Bannerbild German Brest Group - Forschung

Übersicht über Kongressbeiträge von 2018

Mitglieder der German Breast Group präsentierten im Jahr 2018 folgende Beiträge auf internationalen Kongressen:

DGS (Deutsche Gesellschaft für Senologie), 38 Jahrestagung, June 14-16, Stuttgart, Germany

  • Thill M, Seiler S, Decker T et al. A randomized, open-label, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment in patients with hormone receptor-positive, HER2-negative metastatic breast cancer (PADMA); poster
  • Decker T, Barinoff, J, Furlanetto J et al. Anti-hormonal maintenance treatment with/without the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in HR+/HER2- metastatic breast cancer: a phase II trial (AMICA) GBG 97; poster
  • Kümmel S, von Minckwitz G, Vladimirova V et al. Investigating Denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX); poster
  • Loibl S, Jackisch C, Seiler S et al. A randomized, double-blind, phase III trial of neoadjuvant chemotherapy with Atezolizumab/Placebo in patients with triple-negative breast cancer followed by adjuvant continuation of Atezolizumab/Placebo (GeparDouze); poster
  • Furlanetto J, Thode C, Huober J et al. Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neo-/adjuvant chemotherapy (CT) for early breast cancer (EBC); poster
  • Noske A. Tumor infiltrating lymphocytes predict better DFS from intense dose-dense (idd) EPC regimen - results from the German Adjuvant Intergroup Node-positive Study (GAIN-1); oral presentation
  • Reinisch M. Erste Daten der MALE Studie: Welche Hormontherapie ist die effektivste beim Mann?; oral presentation
  • Reimer T. Update INSEMA-Studie; oral presentation

ASCO, June 1-5, Chicago, USA

  • Loibl S, Untch M, Burchardi N et al. Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). J Clin Oncol 36, 2018 (suppl; abstr 104); oral presentation.
  • Möbus V, Noeding S, Ladda E et al. Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting. J Clin Oncol 36, 2018 (suppl; abstr 568); poster.
  • Kümmel S, Wimberger P, von Minckwitz G et al. Investigating denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-paclitaxel schedules: 2x2 factorial design (GeparX)—An interim safety analysis. J Clin Oncol 36, 2018 (suppl; abstr 569); poster.
  • Geyer CE, Loibl S, Rastogi P et al. NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. J Clin Oncol 36, 2018 (suppl; abstr TPS603); poster.
  • Telli M L, Metzger O, Timms K et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. J Clin Oncol 36, 2018 (suppl; abstr 519); poster discussion.
  • Matikas A, Foukakis T, Möbus V et al. Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study. J Clin Oncol 36, 2018 (suppl; abstr 538); poster.
  • Noske A, Weber K, Möbus V et al. Tumor infiltrating lymphocytes to predict DFS from intense dose-dense (idd) EPC regimen: Results from the German Adjuvant Intergroup Node-positive study (GAIN-1). J Clin Oncol 36, 2018 (suppl; abstr 527); poster.
  • Guerini-Rocco E, Gray K P, Munzone E et al. Molecular alterations and late recurrence in postmenopausal women with hormone receptor-positive node-positive breast cancer (BC): Results from the “SOLE” trial. J Clin Oncol 36, 2018 (suppl; abstr 517); poster discussion.
    Denkert C, Untch M, Benz SC et al. Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial. J Clin Oncol 36, 2018 (suppl; abstr 574); poster.
  • Kolberg H-C, Liedtke C, Bauerfeind I et al. Association of clinical/pathological parameters with axillary involvement in early breast cancer in patients with limited sentinel node involvement after neoadjuvant chemotherapy (NACT). J Clin Oncol 36, 2018 (suppl; abstr 559); poster.

Kontakt

Hilal Gökgöz
Tel.: +4961027480-223
Fax: +4961027480-129
E-Mail: Pblctnsgbgd

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd